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Available online 1 August 2016Background: Although new therapeutic approaches for burn treatment havemade progress, there is still need for
bettermethods to enhance wound healing and recovery especially in severely burned patients. Nanoﬁbrillar cel-
lulose (NFC) has gained attention due to its renewable nature, good biocompatibility and excellent physical prop-
erties that are of importance for a range of applications in pharmaceutical and biomedical ﬁelds. In the present
study, we investigated the potential of a wood based NFCwound dressing in a clinical trial on burn patients. Pre-
viously, we have investigated NFC as a topical functionalizedwound dressing that contributes to improvewound
healing in mice.
Methods:Wood based NFC wound dressing was tested in split-thickness skin graft donor site treatment for nine
burn patients in clinical trials at Helsinki Burn Centre. NFC dressingwas applied to split thickness skin graft donor
sites. The dressing gradually dehydrated and attached to donor site during the ﬁrst days. During the clinical trials,
physical and mechanical properties of NFC wound dressing were optimized by changing its composition. From
patient 5 forward, NFC dressing was compared to commercial lactocapromer dressing, Suprathel® (PMI
Polymedics, Germany).
Results: Epithelialization of the NFC dressing-covered donor site was faster in comparison to Suprathel®. Healthy
epithelialized skin was revealed under the detached NFC dressing. NFC dressing self-detached after 11–21 days
for patients 1–9, while Suprathel® self-detached after 16–28 days for patients 5–9. In comparison studies with
patients 5–9, NFC dressing self-detached on average 4 days earlier compared with Suprathel®. Lower NFC con-
tent in the material was evaluated to inﬂuence the enhanced pliability of the dressing and attachment to the
wound bed. No allergic reaction or inﬂammatory response to NFC was observed. NFC dressing did not cause
more pain for patients than the traditional methods to treat the skin graft donor sites.
Conclusion: Based on the preliminary clinical data, NFC dressing seems to be promising for skin graft donor site
treatment since it is biocompatible, attaches easily to wound bed, and remains in place until donor site has
renewed. It also detaches from the epithelialized skin by itself.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Clinical study1. Introduction
Wound healing process represents a complex series of biological
events to restore skin barrier function, prevent dehydration and reduce
the risk of bacterial infection. However, delayed wound healing is fre-
quent andmay lead to chronic inﬂammation, especially in burn patients
with additional systemic impairments [1]. Currently worldwide, burniosciences, Faculty of Pharmacy,
rttula).
. This is an open access article underwound and skin graft donor site treatments vary widely, and a large
number of different wound dressing materials are available for their
treatment [1,2].
Careful wound care is a prerequisite in avoiding infection in burn
treatment. Repeated, painful dressing changes in burn wound areas
and skin graft donor sites often need general anesthesia in the initial
stage. There are myriad of different wound dressings, but none of
them fulﬁlls all the needed requirements. Therefore and especially
when population ages, and incidence of chronic wounds and their risk
factors are increasing, there is an acute need for new advanced wound
care materials that would be applicable also for other types of wounds
such as pressure ulcers.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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thetic materials. The development of ideal wound dressing material is
focused on the requirements of elasticity,moisture andpHmaintenance
in the wound environment. The capacity to prevent bacterial contami-
nation and to promote painless and rapid wound healing are also im-
portant factors [3,4]. Recently, novel silk biomaterial dressings
constituted of nanoscale silk ﬁbers have shown promise for wound
care when studied in vitro in wounded human skin equivalents or in
vivo in the treatment of skin wounds in mice [5–7].
Cellulose based polymers are one of the most abundant natural
products and have a high potential for biomedical and biotechnology
applications [8]. Especially nanoﬁbrillar cellulose (NFC) has attracted at-
tention among researchers during the past years. NFC, which is often
used as a parallel termwith e.g. cellulose nanoﬁbrils, microﬁbrils or mi-
croﬁbrillar cellulose (MFC) is composed of cellulose ﬁbrils of typically
some tens of nanometers in diameter and hundreds of nanometers in
length. High speciﬁc surface area together with highly hydrophilic na-
ture of NFCmake it possible to retain a high amount of water in relation
to its dry matter. When dispersed in water, NFC creates a strong hydro-
gel (Fig. 1A) that can bemodiﬁed for different purposes such as cell cul-
ture scaffold in 0.5% concentration (Fig. 1B) or wound dressing
manufacturing. NFC derived from wood or plant serves as an animal
and human origin-free biomaterial. That makes it interesting in various
applications of human care since the regulatory agencies at Europe, USA
and Japan are looking for the xeno-free biomaterials to be used at pa-
tients' care. Physical and mechanical properties of NFC along with bio-
compatibility promote its widespread application potential in
pharmaceutical and biomedical areas, such as in drug delivery, foams
and aerogels, drug and cell carriers, biomaterial substitutes, and scaffold
synthesis [9–14]. Wood based NFC hydrogels have shown potential for
the formation of three dimensional scaffolds for cell cultures supporting
pluripotency of stem cells, differentiation of liver progenitors and for-
mation of organoid spheroids [15–18]. NFC, having a variety of advan-
tages including strength, non-cytotoxicity and ability to maintain
moisture, is also highlighted as a promising material for clinical
wound healing applications [13,19–22]. Irrespective of promising re-
sults in vitro and in animal studies, clinical studies concerning the use
of NFC in wound healing applications with patients are lacking. A few
studies have shown that bacterial growth is impaired or not supported
in the presence of nanocellulose [20,23], and also the antiviral effects of
the crystalline nanocellulose have been reported [24]. These antimicro-
bial properties would be an advanced characteristic for a wound
dressing.
Different from NFC, carboxymethylcellulose (CMC) hydroﬁber
dressingwith integrated ionic silver has beenwidely studied as a prom-
ising wound dressing material in treatment of burns and ulcers [25].
However, application of CMC dressing in wound treatment usually re-
quires frequent changes of the dressing, which increase the pain burden
on a patient [26]. Further, the use of silver has introduced concerns with
respect to cytotoxicity [25,27,28]. Bacterial cellulose (BC) or microbial
cellulose, on the other hand, has the same sugar-molecule structure as
NFC but is biosynthesized by certain bacterial species. It cannot be re-Fig. 1. A) NFC hydrogel used for manufacturing of the NFC dressing. B) Diluted 0.5% NFC hydrogmodiﬁed into different types of phases like hydrogels and wires as
wood based NFC since to date there exist no effective production
methods to produce strong bacterial cellulose based materials. BC hy-
drogel has been considered as rather weak due to the swelling property
in comparison with many other natural hydrogels [29]. BC mimicking
native extracellularmatrices performs especially as a promising scaffold
material for tissue engineering and for guided tissue regeneration [30,
31]. BC as a wound dressing has been shown to reduce wound closure
time in clinical treatments of leg ulcers and skin tears [32–34]. Further-
more, in clinical trials among severely burned patients it enabled fast
wound healing and showed a high level of adherence to the wound
sites due to its conformability [30,35]. However, BC can be penetrated
by epithelial cells and may therefore integrate into the skin tissue [36].
We have previously shown that NFC containing human adipose
mesenchymal stem cells (hASC) used as a topical functionalized
wound dressing contributes to improve wound healing for nude mice
[[37] Unpublished results]. Moreover, absence of immune rejection
after treatment and the biosafety of NFC alone or in combination with
hASC were conﬁrmed in humanized mice.
In the present study, we aimed to investigate the potential of awood
based NFC wound dressing in a clinical trial among burn patients. NFC
dressing was used for skin graft donor site treatment for nine burn pa-
tients and compared to the commercial lactocapromer based dressing,
Suprathel® (PMI Polymedics Innovations, Germany) at the studies
with ﬁve patients. During the clinical trials, we had an opportunity to
analyse and optimize the physical and mechanical properties of the
NFC dressing.
2. Materials and methods
2.1. Materials
2.1.1. Nanocellulose
Chemically unmodiﬁed wood based NFCwas used for wound dress-
ing manufacturing. The NFC was kindly supplied by UPM-Kymmene
Corporation (UPM), Finland. The NFC, i.e. cellulose nanoﬁbrils, was iso-
lated from bleached birch pulp ﬁbers with a controlled ﬁbrillation and
homogenization process using an industrial ﬂuidizer. After the ﬁbrilla-
tion, solids content of the NFC hydrogel is typically 16 g/l. The NFC
used in this study was speciﬁcally developed for wound healing instead
of the hydrogel used for the 3D cell culture [15].
2.1.2. Production of NFC dressing
NFC dressing was supplied in close co-operation with UPM. Two
principal kinds of NFC dressingsweremanufactured: 100%NFCdressing
(type 1) and reinforced NFC dressing (types 2 and 3; Fig. 1C). Type 1
dressing was manufactured from the NFC hydrogel by applying ﬁltra-
tion technique alike in the in vivo animal experiments. Type 1 dressings
were used for patients 1–2. Types 2 and 3 NFC dressings consisted of an
internal reinforced polyester-viscose based gauze between NFC layers
on the both sides of the gauze. Type 3 had a reduced amount of NFC
compared to the type 2. Dressing type 2 was used for patients 3–5 andel that can serve as cell scaffold in three dimensional cultures C) Reinforced NFC dressing.
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ﬁltrating water. Final water removal was carried out by drying the
dressings under pressure. As the 100% NFC dressing, the reinforced
NFC dressing was manufactured using ﬁltration technique. All the
dressings were cut in shape and packed into sterilization bags. Steriliza-
tion was carried out in Systec V-65 autoclave (Systec GmbH, Germany)
for 15 min at 121 °C.
2.2. Analysis methods of NFC dressing
Sterilized dressings were air conditioned before measuring their
physical andmechanical properties. Air conditioningwas done by keep-
ing the dressings in an air conditioned laboratory room at 23 °C temper-
ature and RH50 for at least 12 h. Measurements (except absorption of
NaCl solution)were carried out according to standardmethods present-
ed in Table 1. 0.9% NaCl solution was produced by UPM from dry NaCl
(J.T. Baker, Netherlands) and distilled water.
2.2.1. Grammage of the NFC wound dressing
Grammage (basisweight)wasmeasured byweighing a dressing of a
speciﬁed area with AG-204 scale (Mettler Toledo, Switzerland).
Grammage is calculated by dividing the NFC dressing weight by the
area of the measured dressing. Thickness measurement was carried
out from a single dressing. Density was calculated by dividing
grammage of the dressing with the thickness of the dressing. Thickness
measurement was carried out by a thickness measurement device
manufactured by Lorentzen & Wettre, Sweden.
2.2.2. Thickness and density of the NFC wound dressing
Thickness measurement was carried out from a single dressing with
L&W Micrometer. Thickness is determined as the distance between
measurement head and sample tray when sample is placed between
them. Density was calculated by dividing grammage of the dressing
with the thickness of the dressing. Thickness measurement was carried
out by thickness measurement device manufactured by Lorentzen &
Wettre, Sweden.
2.2.3. Tensile strength of the NFC wound dressing
Tensile strength was measured by cutting the NFC dressing into
15 mmwide strips and measuring the force needed to break the dress-
ing. 100 mm distance between clamps and an elongation speed of
102 mm/min was used. The tensile tester device L&W Tensile Tester
was produced by Lorentzen & Wettre, Sweden.
2.2.4. Tearing strength of the NFC wound dressing
Tearing strength was measured with Elmendorf-tearing strength
tester (Lorentzen & Wettre, Sweden). Tearing strength was measured
from dressing samples with size of 62 mm × 50 mm. A single sample
was used for each parallel (4) measurement. Tensile and tear results
are presented as a geometric average of the two main directions (x, y)
of the dressing. Geometric average is calculated by multiplying the re-
sult of the twomain directions and taking a square root of the obtained
product of the two measurement values.
2.2.5. NaCl-absorption of the NFC wound dressing
0.9%NaCl absorptionwas carried out by cutting a dryNFC dressing of
a speciﬁc area, weighing and soaking the sample in 0.9% NaCl-solution.Table 1
Standard methods used for measurement of NFC dressing properties [38].
Grammage g/m2 ISO 536
Bulking thickness μm ISO 534
Apparent bulk density kg/m3 ISO 534
Tensile strength kN/m ISO 1924-3
Tear strength mN ISO 1974NaCl-absorption measurement was carried as a series of time (1, 2, 10,
30, 60, 120 and 1440 min). After the selected soaking, the sample was
removed from the 0.9% NaCl solution, placed between plotting boards
and rolled over once with a steel roller (Lorentzen & Wettre, Sweden)
in order to remove the free, non-absorbed 0.9% NaCl solution. Thereaf-
ter, the dressing was weighted by AG-204 scale (Mettler Toledo, Swit-
zerland) and put back into the solution for the next soaking period.
Results are presented as absorbed NaCl solution amount per square
meter of dressing. The used measurement method was modiﬁed from
the standard method described in ISO 535:2014.
2.3. In vitro antimicrobial activity of NFC dressing
NFC dressing was evaluated for antibacterial activity against Staphy-
lococcus aureus ATCC 25923 (S. aureus) and Pseudomonas aeruginosa
ATCC 27853 (P. aeruginosa) using the disk diffusion and macrodilution
broth methods according to EUCAST and CLSI guidelines with slight
modiﬁcations [39,40]. Tests were carried out in aseptic conditions.
For both the disk diffusion and macrodilution broth methods, fresh
Mueller-Hinton agar (MHA; BD Biosciences) plate cultures were pre-
pared from bacterial slant cultures and incubated overnight at
+35 ± 1 °C. NFC dressing samples were prepared by cutting disks of
similar size as of the antibiotic disks (diameter 9 mm) from the sterile
dressing. In disk diffusion assays, penicillin (10 units/disk; Rosco
Diagnostica A/S) and ceftazidime (30 μg/disk; Rosco Diagnostica A/S)
were used as positive controls against S. aureus and P. aeruginosa, re-
spectively. Fresh colonies of both bacterial strains were used to prepare
bacterial suspensions into sterile 0.9% saline. The turbidity of the sus-
pensions was measured by DEN-1B McFarland Densitometer (Biosan,
Latvia) and adjusted to 0.5 McFarland standard [39–41] corresponding
to 1–2 × 108 colony forming units (CFU)/ml. Fresh MHA plates were in-
oculated with bacterial suspensions by spreading with a sterile cotton
swab and the sample disks were applied to the agar plates within
15 min. Plates were incubated at +35 ± 1 °C for 20 h before examina-
tion of the results.
For macrodilution broth assays, ciproﬂoxacin (ICN Biomedicals Inc.)
was used as a positive control at four different concentrations in the
range of 0.125–1 μg/ml and 0.25–2 μg/ml for S. aureus and P. aeruginosa,
respectively. NFC disks were placed into Mueller-Hinton broth (MHB;
BD Biosciences) containing test tubes. Ciproﬂoxacin control samples
were prepared by adding antibiotic stock solution into the control test
tubes. Fresh colonies of both bacterial strains were inoculated into ster-
ile 0.9% saline to prepare bacterial suspensions. The turbidity of bacterial
suspensions was measured with densitometer and CFU/ml value was
calculated. Bacterial suspensions were inoculated into test tubes as a
ﬁnal concentration of 5 × 105 CFU/ml. MHB alone or with NFC, or bacte-
rial suspension alonewere used as negative controls. Suspensions were
incubated at +35 ± 1 °C for 16–20 h, 100 rpm before examination of
the results. Results were observed as the turbidity of samples that was
measured for calculation of CFU/ml value by densitometer. Percentual
bacterial growth was calculated by comparing NFC containing bacterial
suspensionwith bacterial suspensionwithout NFC. Bacterial suspension
test was performed three times.
2.4. In vivo biosafety studies in animals
Animal studies were performed with 100% NFC dressing at the
Centro de Investigación Principe Felipe (CIPF), under the evaluation
and approval from the Animal wellbeing and Research committee in
the center (Committee approval number: 12-0238, CIPF, Valencia,
Spain). In order to evaluate the toxicity of the NFC dressing, a system
for animal full thickness wound healing model in Swiss nu/nu mice
(Charles River) was used as described by [42]. The animals were housed
and closely monitored at the CIPF animal facilities. Sedation was in-
duced by inhalation of isoﬂuorane (2%). Fentanyl (0.05 mg/kg) and
morphine (5 mg/kg) were used for the analgesia during the procedure.
Table 2
Patients and the skin graft donor sites.
Patient
nr
Age Gender Burn
type
TBSA
(%)a
Dressing
type
Body part of NFC
covered SKDSb
SAc of SKDSb covered by
NFC (cm2)
Body part of the Suprathel®
covered SKDSb
SAc of the SKDSb covered by
Suprathel® (cm2)
1 25 Male Electric 5 1 Thigh (front) 8 × 8
2 57 Female Flame 28 1 Thigh (side) 7 × 8
3 21 Male Flame 1 2 Thigh (front) 10 × 10
4 73 Male Flame 11 2 Flank 20 × 15
5 66 Male Flame 16 2 Thigh (right) 25 × 40 Thigh (left) 25 × 40
6 56 Male Flame 10 3 Thigh (right) 20 × 35 Thigh (left) 20 × 32
7 62 Male Flame 47 3 Back 50 × 25 Back 50 × 15
8 56 Female Hot
water
23 3 Thigh (right) 15 × 20 Thigh (right) 15 × 10
9 41 Male Hot
water
10 3 Back 30 × 45 Both thighs 15 × 25
a TBSA= total body surface area.
b SKDS = skin graft donor site.
c SA = surface area.
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of each animal by using a surgical punch with 5 mm of diameter
(BBraun, Spain). One of the injuries was used as control and the other
was covered with the NFC dressing. The number of animals was n =
6. Ten days after the surgery, animals were sacriﬁced by perfusion
through the left ventricle with the aim of preserve all the body. Biopsies
from the injured areawere embedded in parafﬁn and processed for sec-
tioning. The pathological evaluation of the samples was performed by
an independent pathologist.
2.5. Clinical studies of skin graft donor site treatment
2.5.1. Clinical study and patients
Clinical studies with NFC dressing in skin graft donor site treatment
among burn patients were performed at Helsinki Burn Center, Helsinki
UniversityHospital, Helsinki, Finland, from January 2015 toMarch2016.
During the clinical studies, the properties of NFC dressing were devel-
oped further based on the clinical experiences. Nine burn patients,
seven men and two women, needing skin grafting were enrolled in
this study. Average age of patients was 51 years (SD 18), range between
21 and 73 years. Burn injurieswere caused by ﬂames (n=6), electricity
(n= 1) and hot water (n= 2). TBSA% (Total Body Surface Area) values
are presented in Table 2. Patients were selected by a plastic surgeon
based on clinical evaluation. Exclusion criteria were pregnancy, age
under 18 and over 75 years and systemic cortisone treatment. The Re-
search Ethics Committee at the Helsinki University Hospital (HUH)
(99/13/03/02/2014) approved the clinical study. All the enrolled pa-
tients or their legal representatives gave written informed consent be-
fore surgery.
Skin graft donor sites among the ﬁrst patients (patients 1–2) were
small, 8 × 7 cm2, since this was the ﬁrst clinical study to test NFC
wound dressing in patients. Later, the sizes of skin graft donor sites
were up to 50 × 25 cm2. The accurate sizes of all skin graft donor sites
are presented in Table 2. The physical properties of the material wereFig. 2. Treatment protocol with NFCwound dressings in skin graft donor site treatment. A) Skin
sites. C) Donor sites and NFC covered by Vaseline gauze Jelonet®. NFC and Vaseline gauze are at
HUS.developed based on the feedback from clinics throughout the entire
study. Attention was especially paid to the usability of the dressings.
For patients 1–4, NFC dressing was tested alone in skin graft donor
site treatment, but from patient 5 forward NFC dressing was compared
with the commercial synthetic copolymer of polylactide, trimethylene
carbonate, and e-caprolactone, Suprathel® (PMI Polymedic Innova-
tions, Germany), which is regularly used in skin graft donor site treat-
ment at Helsinki Burn Center. Patients' 5 and 6 skin grafts were
harvested from both thighs in equal size; the right thigh was covered
by NFC dressing and the left thigh by Suprathel®. For patient 7, the
NFC wound dressing was placed on large donor site area in the back of
the patient while on previous operation seven days earlier, the other
skin graft donor site in the back of the same patient was covered with
Suprathel®. Donor site of patient 8 was operated in right thigh, and
half of the donor site was covered by NFC wound dressing and the
other half by Suprathel®. For patient 9, NFCwound dressingwas placed
on skin graft donor site in the back, while Suprathel® was used in both
thighs. After discharge, the patients were followed up in the outpatient
clinic up to 11th–75th postoperative day.2.5.2. The in vivo treatment protocol with NFC dressing
Split-thickness skin grafts were harvested by a plastic surgeon using
a Zimmer® air dermatome (Zimmer Inc., Switzerland). Skin graft thick-
ness was 8/1000 in. (0.20 mm), except with the patient 7 where the
thickness was 10/1000 in. (0.25 mm). Hemostasis was achieved using
adrenaline solution soaked Telfa® gauzes (Medtronic, Switzerland). Be-
fore placing NFC dressing on the donor site, it was soaked in 0.9% NaCl
solution. NFC dressing was covered by Jelonet® (Smith & Nephew,
UK) and ﬁxed with staples (Fig. 2). Dry dressings were used as the out-
ermost covering material. Suprathel® was covered in the same way as
NFC dressing but it was not immersed in 0.9% NaCl before placing on
the donor site. Dressings were not changed during the entire treatment
period.after harvesting of 0.25mm grafts. B) NFCwound dressings placed on the skin graft donor
tached to skin by staples and covered by dry dressings. ©T Hanski, P Hatanpää, S Rajander,
140
160
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We investigated the healing of the donor site that was determined
by the self-detachment of material from the skin graft donor site. Desig-
nation was based on material property to detach itself from the skin
graft donor site after the skin was epithelialized. During the clinical
treatments, NFC dressing material was evaluated in terms of strength
and pliability. NFCwound dressingswere checked by visual observation
without changing thematerial at intervals of few days until the self-de-
tachment, and the photos were collected during the examination of
donor sites and wound dressings throughout the clinical NFC dressing
periods. Evaluation of the skin condition and epithelialization was
done by a burn surgeon. In addition, the possible adverse effects were
evaluated and subjective pain experience was asked from the patients.
3. Results
3.1. Characteristics of NFC wound dressing
NFC dressing properties were measured according to the methods
presented in Table 1. Grammage, thickness and density describe basic
physical properties of the dressings whereas tensile and tearing
strength present the mechanical properties and ability of the dressing
to resist fracturing. Tensile strength presents how the dressing with-
stands forces affecting in the direction of the plane of the dressing. Tear-
ing strength measures the out-of-plane strength of the dressing.
Strength is needed e.g. to resist the forces caused by ﬁxing the dressing
with staples. NFC wound dressing properties are presented in Table 3.
100%NFCdressingwith grammage of 61,5 g/m2wasused for thepa-
tients 1–2. 100% NFC dressing produces a high density and a high in-
plane tensile strength. However, this dressing was too brittle to resist
fracturing at ﬁxing points of staples.
For patients 3–5, a reinforcement gauzewas introduced and the total
amount of NFC was simultaneously reduced from 100% to 60% of the
total weight of the dressing. The effect of the gauze can be seen as great-
ly increased thickness of the dressing and resulting in lower density of
the dressing. For patients 6–9, the NFC amount in the dressing was fur-
ther reduced to 50% of the total weight of the dressing in order to speed
up wetting and to make the dressing more conformable.
The grammages of the NFC dressing type 1 (patients 1–2) and rein-
forced NFC dressing type 3 (patients 6–9) were close to each other. Be-
cause of the reinforcement gauze, the amount of the NFC per square
meter in the reinforced NFC dressing was, however, almost 50% lower
than that in the NFC dressing used in patients 1–2. A slight decrease in
in-plane tensile strength was noticed due to the lower amount of NFC
whereas a major increase in tearing strength was seen. No fracturing
of the dressing was seen after the reinforcement gauze was introduced.
The thickness of the gauze largely determines the thickness level of
the dressing, which can be seen with no difference in the thickness of
the dressing used for patients 3–5 and 6–9. Thickness was measured
from the dry dressings. Thickness ofwetted dressings has not beenmea-
sured but ﬂuid absorption affects the thickness.Table 3
The properties of NFC wound dressing.
Dressing properties/dressing type,
patients
1, 1–2
(STD)
2, 3–5
(STD)
3, 6–9
(STD)
Reinforcement gauze No Yes Yes
Grammage of dressing/m2 61.7 (0.6) 78.5 (5.7) 66.2 (4.45)
Grammage of reinforcement gauze/g/m2 32.5 32.5
NFC grammage in dressing/g/m2 61.7 46 32.5
Thickness/μm 58 (2) 130.5 (5.1) 150 (1.4)
Density/g/cm3 1073 (40) 618 (35) 428 (6.8)
Tear strength, geom ave/mN 63 (1.7) 2308 (381)
Tensile strength, geom ave/kN/m 3.6 (0.9) 2.8 (0.29)
Saline absorption @ 2 min/g/m2 38.4 (7.4) 91.0 (9.5) 77.3 (6.2)
Saline absorption @ 2 min/g/g 0.62 (0.10) 1.05 (0.04) 1.11 (0.04)NaCl absorption was measured in order to describe the capability of
the dressing to absorb ﬂuids. Based on the absorption measurements
carried out, it was seen that the initial wetting of the NFC dressing
was very fast and took place within one minute. Thereafter the absorp-
tion speed reduced but the NFC dressing was still able to absorb after
24 h of soaking. The amount of absorbed NaCl in the three different
NFC wound dressings is presented in Fig. 3.
100% NFC dressing used for patients 1–2 absorbed about 50% less
than the NFC dressings used for patients 3–5 and 6–9, in which the
amount of NFC was reduced from 100% to 60% and 50% of the total
weight of the dressing. The higher amount of NFC in the dressing used
for patients 1–2 should have given a higher absorption capacity but it
seemed that the combination of gauze and NFC used for patients 3–9
did provide favorable conditions for absorption. It is also supposed
that the higher NaCl and ﬂuid absorption capability of NFC dressing im-
proved the attachment of the dressing to wound bed.
NFC dressings used for the patients 3–5 absorbed NaCl and body
ﬂuids lightly more than the NFC dressings used for the patients 6–9.
This ismost probably due to the higher NFC content in theNFC dressing.
However, the reducedNFC amount in theNFC dressing used for patients
6–9made the dressingmore pliable, whichwas beneﬁcial from the NFC
dressing usage point of view.
3.2. The antimicrobial activity of NFC dressing
NFC dressing was tested for antibacterial effect against Gram-posi-
tive (S. aureus) andGram-negative (P. aeruginosa) bacteria by disk diffu-
sion and macrodilution broth methods. No zones of growth inhibition
against these bacteria were observed around the NFC dressing disk
(the zones observed for positive controls were according to CLSI guide-
lines). According to our results based on bacterial suspension assays, the
presence of NFC dressing in the culture media did not alter signiﬁcantly
the growth of S. aureus and P. aeruginosa compared to control suspen-
sion containing only bacteria.
3.3. In vivo animal biosafety assessment
To analyse any toxic effect of thematerial after contact with an open
injury, the NFC dressing was evaluated using a Swiss nu/nu mouse full
thickness skin wound healing model (Fig. 4A–C). In all the cases, the
100% NFC dressing, the same one used with the patients 1–2, detached
itself around day 8–9. Histopathological evaluation of the injured area
performed by an independent pathologist demonstrated the absence
of pathological response. The anatomical structure and appearance of
the injured areas in contact with the NFC dressing and their correspon-
dent controls were similar (Fig. 4D and E, respectively). No evidences of
cell necrosis, granulomas or giant cells were founded in any of the cases0
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Fig. 3. The amount of absorbed 0.9% saline in NFC wound dressings.
Fig. 4. Full thickness nudemicemodel and the histopathological analysis of the effect of NFCdressing at the site of injury. A) Coverage and sealing of control and treated area after the injury
induction. B) Aspect of both control and treated (dressing-covered) injuries (5 POD). C) Evolution of the area at day 10. TheNFC dressing covering thewound area detached itself from the
animals after 8–9 days. D) Photomicrography of the control injury stained with hematoxylin and eosine ten days after the surgery (Scale = 200 μm). E) Photomicrography of the injury
treated with NFC dressing ten days after the surgery. No signals of giant cells, granuloma, tumor or eosinophils were detected in the animals (Scale = 200 μm).
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highlighting the lack of allergic reaction by NFC contact. Absence of bio-
chemical response and inﬂammation has also been assessed in human-
ized mice, and these results with results of Swiss nu/nu animals have
been described in detail in [[37] Unpublished results].
3.4. Clinical studies of skin graft donor site treatment
After the animal in vivo safety studies of the NFC dressing were con-
ﬁrmed inmice, the ﬁrst in vivo clinical tests in skin graft donor site treat-
ment were initiated.
Epithelialization rate of skin graft donor sites under both of the NFC
dressing and the Suprathel® were evaluated by determining the post-
operative day when the material self-detached from the skin graft
donor site and the healthy epithelialized skinwas revealed. Detachment
of theNFC dressing from epithelialized skin graft donor site is presented
in Fig. 5. Among patients 1–9, epithelialization of the skin graft donor
site with the NFC wound dressing took 16 days as an average (rangeFig. 5. NFC wound dressing in skin graft donor site of patient 9 on 13th POD. A) Figure shows a
donor site. B) Figure zoomed from Panel A. ©T Hanski, P Hatanpää, S Rajander, HUS.between 11 and 21, STD 4). In comparison studies (patients 5–9), NFC
self-detached on average on 18th postoperative day (range between
13 and 21, STD 3), while Suprathel® self-detached on 22nd POD
(range between 16 and 28, STD 4). Compared to Suprathel®, NFC dress-
ing self-detached fewdays earlier in 4 cases out of 5. In one case, thema-
terials self-detached at the same day. Self-detachment dates are
presented in Table 4. There were no major complications related to
the use of NFC.
When the NFC dressing trials started with the ﬁrst patient, the used
100% NFC dressing was very stiff and fragile. Therefore attention was
paid to develop a more pliable and stronger NFC dressing, which was
achieved along with the clinical tests with the patients for the skin
graft donor site treatment. With the patient 1, the stiffness and fragility
of NFC dressing, whichwas 100% of NFC, did not cause any harm for the
patient, and the skin graft donor site healed well within 17 days. With
the patient 2, the NFC dressing treatment was interrupted at the ﬁrst
postoperative day due to premature detachment of the NFC dressing
probably because of the too high stiffness of the NFC dressing.special characteristic of NFC wound dressing: it self-detaches the epithelialized skin graft
Table 4
Detachment days of the wound dressings (postoperative days).
Patient
nr
NFC
dressing
type
Body part of NFC
covered SKDSa
SAb of SKDSa covered by
NFC (cm2)
NFC
detachment
PODc
Body part of Suprathel®
covered SKDSa
SAb of the SKDSa covered by
Suprathel® (cm2)
Suprathel®
detachment PODc
1 1 Thigh (front) 8 × 8 11
2 1 Thigh (side) 7 × 8 Discontinued
3 2 Thigh (front) 10 × 10 11
4 2 Flank 20 × 15 Discontinued
5 2 Thigh (right) 25 × 40 17 Thigh (left) 25 × 40 22
6 3 Thigh (right) 20 × 35 17 Thigh (left) 20 × 32 21
7 3 Back 50 × 25 21 Back 50 × 15 28
8 3 Thigh (right) 15 × 20 21 Thigh (right) 15 × 10 21
9 3 Back 30 × 45 13 Both thighs 15 × 25 16
a SKDS = skin graft donor site.
b SA = surface area.
c POD= postoperative day.
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dressing structure. The reinforced NFC dressing used for patients 3
and 4 appeared to be strong and pliable. No problems were reported
in case of the patient 3. For the patient 4, the donor site treated with
NFC dressingwas infected. However, with the same patient 4, the infec-
tion was present also in another donor sites as well as in burned areas
treated with different materials. Therefore, the clinical test with the pa-
tient 4 was discontinued due to the infection.
The ﬁrst comparisons with the different wound dressing materials
were performed with the patient 5, for which both NFC dressing and
Suprathel® was applied. According to the self-detachment dates and
the clinical evaluation concerning skin condition, NFC dressing during
skin graft donor site treatment performed better than Suprathel®. On
the 75th POD, skin condition in donor site covered by NFC dressing
did not differ from the donor site treated by Suprathel®. The stiffness
of the reinforcedNFCwounddressingwas still concerned to be too high.
Among the patients 6–9, NFC dressing was developed further to-
wards better usability. No problems were recorded for patient 6 due
to the use of NFC wound dressing. For the patient 6, NFC dressing self-
detached the skin graft donor site area completely four days before
Suprathel®. In the case of the patient 7, NFC dressing self-detached
from the donor site seven days earlier than Suprathel® but after the de-
tachment of the materials, skin tears were revealed under both NFC
dressing and Suprathel® (Fig. 6). In the case of patient 8, both of theFig. 6. Skin graft donor site treatment in patient 7. A) Skin graft donor sites in operation. Suprath
NFC wound dressing attached well to the skin. On POD 3, dressings were still moist. C) On POD
shownwith asterisks. D) POD15. NFChas partially self-detached from the donor sites, just like S
have self-detached. ©T Hanski, P Hatanpää, S Rajander, HUS.materials self-detached from the donor site at the same day (Fig. 7).
However, few days after materials had detached, inﬂammationwas no-
ticed in the donor site covered by Suprathel® (Fig. 7C). In the case of pa-
tient 9, NFC dressingperformedwell in donor site treatment in theback:
it stayed still in place and detached the donor site on the 13th POD.
Suprathel® detached from the thighs of the same patient on the 16th
POD.
No allergic reaction to NFC dressings were reported in any of the pa-
tients. The reinforced and further modiﬁed NFC dressing exhibited the
hoped and correct elasticity with appropriate adherence to the wound
of the patient. It is also worthy to notice, that the NFC dressing did not
cause more pain for patients than the traditional methods to treat the
skin graft donor sites.
4. Discussion
Based on these in vivo clinical studies with nine patients, NFC dress-
ing seems to be very promising material for skin graft donor site treat-
ment among burn patients. Before the clinical studies in small donor
sites, NFC dressing was tested ﬁrst in vivo in nu/nu mice to evaluate
the biocompatibility and ensure the absence of any toxic effect triggered
by thematerial. Indeed, no pathological response was observed inmice.
After promising primary results with the ﬁrst three patients, the treat-
ment was expanded into large and challenging skin graft donor siteel® that was placed onto donor site seven days earlier is shown on topwith an asterisk. B)
7, NFC dressings had dried and were still in place. Donor sites covered by Suprathel® are
uprathel® (shownwith asterisks). E) POD21. NFC and Suprathel® (markedwith asterisks)
Fig. 7. Skin graft donor site treatment in patient 8. A) NFC dressing (transparent) placed on donor site on the left, Suprathel® (white) on the right. B) Skin graft donor site on dressing
detachment day 21st POD. C) Donor site area treated with Suprathel® (on the right) shows irritation. D) Skin graft donor sites and wound dressings on 18th POD. NFC dressing is
shown in the left, Suprathel® in the right. E) Epithelialized donor site under the Suprathel® (asterisk) and NFC on 18th POD. ©T Hanski, P Hatanpää, S Rajander, HUS.
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concerning biocompatibility between the human tissue and NFC dress-
ing. Skin graft donor sites epithelialized well in all patients treated with
NFC dressing until its self-detachment.
Essential characteristic for a wound dressing is its ability to absorb
secreted wound ﬂuid as well as easy removal from the wound after ep-
ithelialization. Gauzes traditionally used as skin dressing materials
show large permeability but tight adhesion on thewound bed, inducing
unnecessary pain on removal [43]. Both NFC dressing and Suprathel®
attached to the wound bed and protected the skin graft donor site.
After the skin graft donor site was epithelialized, bothmaterials self-de-
tached from the donor site itself without any discomfort on removal.
Based on this, epithelialization rate of the skin graft donor site was eval-
uated by determining the time elapsed between skin graft harvesting
andmaterial detachment from the donor site. According to our compar-
ison studies, NFC dressing self-detaches from the donor site on average
of 18 days, while Suprathel® in 22 days. Although n value of our clinical
studywas small and in all cases the areaswere not comparable in terms
of anatomical areas, the results were consistent. In the case of the pa-
tient 7, NFC dressing was placed on the skin graft donor site in the
back while Suprathel® was placed to thighs. In this case, NFC dressing
self-detached on 13th postoperative day and Suprathel on 16th. Central
sections of the body (back)may healmore efﬁciently than distal regions
(thighs) but on the other hand, more rubbing may be directed to the
back compared to thighs. In the cases of the patients 5 and 6, NFC dress-
ing and Suprathel® covered the similar donor site areas; the other ma-
terialwas placed on the right thigh and the other on the left. Also among
these patients, self-detachment of Suprathel® took 3–4 days longer
than the self-detachment of NFC dressing.
Biocompatibility of NFC has been reported in previous studies [9,15].
According to our clinical experience, NFC dressing did not cause any ad-
verse reactions. However, thismust be conﬁrmed in our further planned
studies by evaluating the presence of inﬂammation markers from pa-
tient biopsies and blood samples. Although NFC dressing may not
show property of tissue repair by itself, it may serve as biocompatible
and nontoxic matrix for cells and proteins that contribute to natural re-
pair processes.
Suprathel®has been proved to be biocompatiblematerial, andno al-
lergic reactions are reported [44–51]. In two comparison studies out of
ﬁve, we registered some irritation in skin graft donor sites covered by
Suprathel® after the material was detached. Irritation was not present
in the donor site areas covered by NFC dressing (Fig. 7). Phenomenoncausing irritation is not clear, but it is a subject to be studied. Initial pH
of the Suprathel® is 5.5, and in vitro it can decrease down to pH 4. Initial
pH of the NFC is typically 6–7. Regulation of the pH value has thought to
be beneﬁcial especially in treatment of chronic wounds, which usually
show decreased H+ concentrations. Decreasing the pH may be beneﬁ-
cial due to increase in antimicrobial activity, release of oxygen, and re-
duction of toxicity caused by bacterial end product [52,53]. Decreased
pH leading to alteration in protease function may have positive or neg-
ative effects on wound healing, since the balance between matrix
metalloproteases (MMPs) and tissue inhibitors of MMPs (TIMPs) is im-
portant [54,55]. However, keratinocyte function and re-epithelialization
may be impaired due to pH reduction down to 5 [56]. Therefore, it is a
subject to be considered, if it is necessary at all to decrease the pH
level in the treatment of skin graft donor site.
Regarding the possible antimicrobial properties of wound dressing
materials, NFC dressing used in the present study did not signiﬁcantly
affect the growth of common wound pathogens Staphylococcus aureus
and Pseudomonas aeruginosa in bacterial suspension. These results sug-
gest that NFC dressing do not have antibacterial properties but neither
does it support bacterial growth. Previously, nanocellulose diluted in
deionised water and used as a suspension with bacterial growth medi-
um was shown to reduce the growth of P. aeruginosa [20]. Powell et al.
also demonstrated an increased potential for NFC to impair bacterial
bioﬁlm growth compared to CMC wound dressing material [19]. It
may be possible that NFC dressing used in wound care forms a physical
water layer-based barrier towards external microoganisms and entraps
bacteria within its ﬁbers. If required, antimicrobial activity can be intro-
duced by conjugation of antimicrobial agents such as silver particles
(Ag) or antiviral agents like tyrosine sulphate mimetic ligands into the
nanocellulose biomaterial [24,57–59].
During the clinical trial, the relationship between NFC content and
pliability of the dressing became evident. Among the ﬁrst patients, the
material was too stiff and fragile, but after decreasing the NFC content
in the dressing the pliability and adsorption capacity was signiﬁcantly
enhanced. NFC is very hydrophilic thanks to its high amount of hydroxyl
groups. Hydrophilicitymay contribute to the performance of NFC dress-
ing by forming a water ﬁlm between the dressing and the wound sur-
face. Our tentative hypothesis is that the water ﬁlm forms a favorable
environment for skin regeneration. In addition, the water ﬁlmmay pre-
vent integration of the dressing into the tissue. Biocompatibility of NFC
is important not only in wound dressing applications as such but in of-
fering a possibility to use NFC dressing as a carrier for cells or bioactive
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NFC having a porous network structure may be useful for potential
transportation of antibiotics or other drugs into the wound while pro-
viding an effective physical barrier against infections [60].
We have continued to further studies concerning the use of NFC
dressing in skin graft donor site treatment. Our aim is to extend the clin-
ical trial to a larger comparison study betweenNFCwound dressing and
Suprathel®. Moreover, further studies will include the collection of bi-
opsies and blood samples from the patients in order to study wound
healing and inﬂammation in skin graft donor sites. In addition, the qual-
ity of the epithelialized skin should be determined by a standardized
method, and the pain experienced by patients will be evaluated by
VAS (visual analogic scale).
5. Conclusion
In the present study, NFC seemed to be highly biocompatible in the
treatment of skin graft donor sites. NFC dressing adhered well to the
wound bed and detached from thewound surface itself after skin recov-
ery. According to preliminary comparison studies with NFC dressing
and Suprathel®, epithelialization under the NFC dressing seemed to
be faster compared with Suprathel®. However, further studies are re-
quired in order to evaluate the capacity of NFC dressing to promote
thewound healing process. In the future, also other forms of complicat-
ed wound processes constitute a potential application area for NFC
dressing.
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